Merrill Lynch Reiterates a Buy Rating on Orexigen
In a report published on January 2, Steve Byrne from Merrill Lynch reiterated a Buy rating on Orexigen (NASDAQ: OREX), with a price target of $10. The company’s shares closed last Friday at $6.30.
Orexigen has an analyst consensus of Strong Buy, with a price target consensus of $10.
The company has a one year high of $7.82 and a one year low of $3.11. Currently, Orexigen has an average volume of 3.53M.
According to TipRanks, Byrne is a 4-star analyst with an average return of 12.0% and a 47.4% success rate. Byrne covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Pacira Pharmaceuticals, and Coronado Biosciences.
Orexigen Therapeutics Inc is a biopharmaceutical company. The Company is engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product candidate includes NB32 and Empatic.
